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Abstract (english):  
 
Background: Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to 
previously irradiated skin subsequent to the administration of certain chemotherapeutics. Here we 
present a rare case of RRD induced by the oral multikinase inhibitor sorafenib.  
Case report: A 77-year old male with hepatocellular carcinoma was irradiated at ten different sites for 
bone metastases with 20-36 Gray in 5-12 fractions from January to March 2015. Sorafenib 400 mg 
was started twice daily in mid-March. One week later the patient presented with fever and various 
erythematous lesions in the right upper arm, mandible and trunk confined to irradiated areas. After 
RRD was diagnosed by exclusion of other causes and skin biopsy, sorafenib was paused and with the 
administration of topical corticosteroids and oral antihistamines the skin reaction subsided within 
several days. Sorafenib was re-administered after 3 weeks and did not lead to re-occurrence of RRD.  
Only four other such cases have been reported in the literature and WHO pharmacovigilance 
database on individual case safety reports. Our report is the first with a potential relation between the 
severity of Sorafenib-induced RRD and the radiation dose, the histopathological features, and 
simultaneous acute radiation dermatitis and mucositis.  
Conclusion: RRD induced by sorafenib is a rare phenomenon, but should be considered in patients 
showing erythematous skin lesions 1-2 weeks after initiation of the drug preferentially in areas where 
skin has been irradiated with more than 30 Gy equivalent dose. Discontinuation of sorafenib and re-
administration should be considered depending on the clinical situation. 
 
 
 
Abstract (deutsch):  
 
Hintergrund: Recall-Strahlendermatitis (RRD) ist eine akute Entzündungsreaktion der Haut in zuvor 
bestrahlten Arealen, welche meist nach Einnahme bestimmter Chemotherapeutika auftritt. 
Nachfolgend präsentieren wir einen seltenen Fall von RRD unter Therapie mit dem Multikinase-
Inhibitor Sorafenib. 
 
Fallbeschreibung: Ein 77-jähriger, männlicher Patient mit ossär metastasiertem hepatozellulärem 
Karzinom wurde zwischen Januar und März 2015 an insgesamt 10 verschiedenen Lokalisationen mit 
20-36 Gray in 5-12 Fraktionen bestrahlt. Sorafenib 400 mg wurde ab Mitte März zweimal täglich 
verabreicht. Eine Woche später entwickelte der Patient Fieber und erythematöse Läsionen am rechten 
Oberarm, Unterkiefer und Rumpf. Die Hautveränderungen waren allesamt auf zuvor bestrahle Areale 
begrenzt. Nach Ausschluss anderer Ursachen mittels Biopsie einer der Hautveränderungen wurde die 
klinische Diagnose einer RRD gestellt. Sorafenib wurde pausiert und topische Kortikosteroide sowie 
orale Antihistaminika verabreicht, woraufhin die Hautreaktionen abklangen. Eine erneute Gabe von 
Sorafenib nach insgesamt dreiwöchiger Pause führte zu keiner neuerlichen Hautreaktion. 
Nur vier weitere Fälle von RRD unter Sorafenib wurden bislang weltweit berichtet. Im vorliegenden 
Fall werden erstmals ein potentieller Zusammenhang des Schweregrads der RRD unter Sorafenib mit 
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der Bestrahlungsdosis der Haut,  die histopathologischen Veränderungen sowie eine gleichzeitig 
vorliegende akute Strahlendermatitis und Mukositis dargestellt. 
 
Schlussfolgerung: Durch Sorafenib hervorgerufene RRD ist ein seltenes Phänomen, welches als 
erythematöse Hautreaktion 1-2 Wochen nach Therapiebeginn mit der Substanz in bestrahlten 
Hautarealen auftritt. Eine Therapiepause mit möglichem Wiederbeginn von Sorafenib sollte abhängig 
von der klinischen Situation und dem Schweregrad der Reaktion evaluiert werden. 
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Background 
Radiation recall dermatitis (RRD) is defined as an acute inflammatory reaction confined to previously 
irradiated skin occuring usually months to even years after the administration of certain drugs, mostly 
classical chemotherapeutics [1]. 
Sorafenib is an oral multikinase inhibitor and targeted anticancer substance and is indicated for the 
treatment of unresectable hepatocellular carcinoma (HCC), advanced I-133-refractory thyroid 
carcinoma or advanced, pre-treated renal cell carcinoma [2]. Most common adverse effects of 
sorafenib include gastrointestinal with abdominal pain, diarrhea and nausea, hepatic with elevated 
levels of liver enzymes and dermatologic with palmar-plantar erythrodysesthesia (hand-foot reaction), 
alopecia and rash [3-5]. Here we present a rare case of RRD induced by sorafenib in a patient 
irradiated for several bone metastases from his hepatocellular carcinoma (HCC). A systematic review 
of published cases in the scientific literature and the WHO pharmacovigilance database was 
conducted to identify risk factors, signs and course of this reaction and outcome. 
 
 
Case study 
A 77-year old male Caucasian (weight 67 kg, height 160 cm, BMI 26 kg/m2) with Hepatitis C 
associated HCC (diagnosis in 04/2014) received radiation to several metastatic bone sites between 
January and March 2015. The radiation dose was 20-36 Gray (Gy) delivered in 5-12 fractions (Table 
1) which resulted in a good analgetic effect with improvement of patient’s mobility. Sorafenib was 
started at a dosage of 200 mg orally twice daily in mid-March with slow dose increments. Long-term 
co-medication included amlodipine, metoprolol, hydrochlorothiazide for hypertension, tamsulosin for 
prostatic hyperplasia, oxycodone for pain and esomeprazole for gastric ulcer prophylaxis.  
One week after initiation of sorafenib the patient presented with fever (38.2°C), rising CRP (23 mg/l) 
and a painless erythematous lesion at the right elbow where he had been operated for pathologic 
fracture and had received postoperative irradiation with 12 x 3 Gy. Blood pressure, heart rate and 
oxygen saturation were unchanged compared to baseline values (blood pressure 150/80 mmHg, pulse 
rate 91/min., oxygen saturation SpO2 92%). Assuming a local skin-infection antibiotics (1 g amoxicillin 
/ 200 mg clavulanic acid every 8 hours i.v.) were started. As per schedule, the dose of sorafenib was 
escalated to 400 mg twice daily and in the following days the erythema spread proximally into a 
distinct rectangular shape equivalent to the previous irradiation field. In addition, other skin lesions 
evolved, all of them in currently (acute radiation dermatitis, ARD) or previously irradiated areas 
(radiation recall dermatitis, RRD) (Figure 1, Table 1). RRD was suspected and sorafenib was stopped 
one week after the first symptoms occured. Affected skin areas included currently and previously 
irridated areas like mandible, humerus, scapula and spine. Multiple erythematous papules and 
plaques resulted in dermatitis grade 1 – 3 according to the common terminology criteria for adverse 
events version 4.0 (CTCAE) [6]. The severity of dermatitis showed a potential relation with the 
administered radiation dose, because ≥ grade 2 skin toxicity predominantly occurred when the 
maximal skin dose was above 30 Gy (Table 1). In addition the patient developed an urinary retention 
and severe mucositis CTCAE grade 2. Topical therapy of the skin lesions with corticosteroids 
(betamethasone, clobetasol) and systemic oral antihistamines (fexofenadine 180 mg twice daily) were 
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administered. Blood cultures remained negative. The patient developed a generalized eczematous 
skin reaction with severe pruritus. A skin biopsy of an erythematous lesion localised on the right chest 
revealed diffuse perivascular lymphohistiocytic infiltrate with few eosinophils in the corium and 
apoptotic keratinocytes and distinct vacuolisation in the junction zone (Figure 2).  
The skin reaction decreased within 14 days after termination of sorafenib. After an interval of 3 weeks 
sorafenib was restarted in a reduced dosage of 200 mg twice daily. The skin reaction did not worsen, 
but the patient developed fluctuating fever, so eventually sorafenib was discontinued after another 
week.  
 
Systematic Review and Discussion 
We present a case of increased skin toxicity and severe mucositis shortly after initiation of sorafenib: 
with worsening acute radiation induced dermatitis in areas currently under treatment (acetabulum, SIJ, 
L1, mandible), and RRD in previously irradiated areas (scapula, humerus, T3, T6, T10, 8th rib) (see 
Table 1).  
The radiosensitizing effect of sorafenib in combination with radiotherapy has been shown in different 
cell lines [7-11]. Peters et al. reported on a patient receiving sorafenib and irradiation for his lumbar 
metastasis of a renal cell carcinoma who died of severe bowel complications after radiotherapy [12].  
In contrast to other cutaneous complications of molecularly targeted therapies such as hand-foot skin 
reaction, RRD induced by sorafenib is a rare phenomenon. In large clinical trials in patients with HCC, 
who received sorafenib in combination with radiotherapy, cases of RRD were not reported [13, 14]. 
Similarly, no known reactions have been reported after treatment of gliomas [15, 16], pancreatic 
cancer [17, 18] or sarcoma [19-21]. 
We performed a systematic search for RRD induced by sorafenib in MEDLINE (“radiation recall 
dermatitis sorafenib”; “recall sorafenib”) and the WHO global database “VigiBase®” in 
pharmacovigilance [22]. So far, only 3 cases have been reported in the literature (Table 2). Hsieh 
described a RRD in a patient with HCC after intensity modulated radiotherapy (IMRT) of the liver with 
48 Gy and start of sorafenib 300 mg twice daily ten days after SBRT. A well defined skin lesion at the 
right upper abdomen appeared 1 week after start of sorafenib and resolved 10 days after stopping the 
drug and local therapy with clobestasol propionate [23]. Oh and collegues observed an erythematous 
lesion with dry desquamation on the right chest wall in a patient with HCC, irradiated for a chest wall 
mass with 39 Gy. After completion of radiotherapy sorafenib was started with 400 mg twice daily and 
the skin lesion occurred after 14 days. Another 10 days later, the patient presented with a 
disseminated exanthematous rash and severe pruritus. Sorafenib was stopped and an oral 
antihistamine was prescribed. One week later, the symptoms resolved and sorafenib was restarted 
without any further skin reactions [24]. Chung et al. presented a case of a 38-year old male with liver 
metastases treated with palliative radiotherapy (6 x 5 Gy). Three weeks after completion of 
radiotherapy sorafenib was started with 200 mg twice daily. Several days later the patient presented 
with pruritus of the left posterior flank, hyperpigmentation and dry desquamation in the previously 
irradiated areas. Sorafenib 200 mg twice daily was continued and a topical steroid cream was 
administered. The pruritus and skin reaction resolved 2-3 weeks later. The dose of sorafenib was 
escalated to 400 mg twice daily. No further exacerbations of the RRD occurred [25]. In the 
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pharmacovigilance database only one other case of “recall phenomenon” and sorafenib was identified. 
Sorafenib was the only suspected drug in a 51-year old male with metastatic renal cell carcinoma. 
Other reported symptoms included vesicular rash, swelling, tenderness and pain. All reported patients 
with sorafenib associated RRD were male with a median age of 51 years and an average daily dose of 
575 mg (range: 300 – 800 mg) of sorafenib. Symptoms started early after initiation of sorafenib within 
1-2 weeks. 
The leading symptoms in the reported cases include erythematous skin lesions localized in areas of 
previous radiation exposure marked by disseminated exanthematous rash, pruritus and pain. RRD 
caused by other chemotherapeutics occurred frequently with an interval between radiotherapy and 
chemotherapy of less than 2 months [26]. A dose reduction or discontinuation of sorafenib together 
with systemic steroid therapy, antihistamines and local treatment led to rapid improvement of 
symptoms. Rechallenge with the agent did not lead to symptom recurrence. 
There seems to be a radiation dose dependence of the severity of RRD. In contrast to other case 
reports with RRD after initiation of sorafenib, our patient was irradiated at several different 
localisations with different radiation doses. He developed pronounced RRD in areas of the skin 
irradiated with a minimum of 30 Gy equivalent skin dose (see Table 1). Especially lesions near to the 
body surface and irradiated with 3D-conformal radiotherapy are associated with high skin doses and 
are therefore more prone to RRD. Radiation dose-dependent RRD has also been reported after 
treatment with bleomycin and docetaxel, respectively [27, 28]. Interestingly, the first occurrence of 
RRD in our patient was at the right upper arm, where he had received postoperative radiotherapy after 
osteosynthesis of a pathological humerus fracture. The RRD might have been triggered by the 
postoperative inflammatory environment. Other authors hypothesized that potential triggers might be 
impaired epithelial function induced by radiation effect on epithelial stem cells, changes in 
vascularization or DNA repair [29]. 
Sorafenib is an inhibitor of multiple intracellular and cell surface kinases. It blocks Raf kinases, which 
mediate cell proliferation and differentiation, and inhibits angiogenesis including vascular endothelial 
growth factor receptor [30]. The pathogenesis of RRD induced by sorafenib is unknown – reaching 
from an idiosyncratic hypersensitivity reaction, a defect in DNA repair to a direct toxic effect of the 
respective agent [31]. Skin biopsy, which was not performed in previous reports, demonstrated in our 
patient vacuolization of the dermoepidermal junction, apoptotic keratinocytes with sparse perivascular 
infiltrate of lymphocytes and eosinophils (Fig 2). The histological picture mimicked the pattern of graft-
versus-host reactions of the skin or cutaneous drug allergies.  
Radiation recall reactions followed by sorafenib might not only be confined to skin reactions; 
cardiotoxicitiy has also been described [32]. A patient following irradiation of her lung cancer and start 
of sorafenib 5 months after radiotherapy presented with edema in the basal and mid anterior wall of 
the heart muscle matching to the previously irradiated area [32]. In addition to augmentation of acute 
skin reaction sorafenib might also enhance acute mucosal toxicity. Our patient displayed enhanced 
mucosal toxicity in the oral cavity and the urethra with urinary retention in response to radiotherapy of 
the mandible and the pelvic region, which might be related to the radiosensitizing effect of sorafenib 
described above. 
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Conclusion 
RRD induced by sorafenib is a rare phenomenon. The severety of the reaction seems to be radiation 
dose dependent (mainly after 30 Gy equivalent dose to the skin). Adverse reactions typically appear 1-
2 weeks after commencing sorafenib. Besides, systemic reactions like fever and rash can also occur. 
RRD is a clinical diagnosis. Histologic sampling might be performed to exclude other causes of skin 
conditions. Therapy of RRD consists of discontinuation of sorafenib, treatment with topical steroids 
and/or oral antihistamines. A rechallenge with sorafenib could be considered depending on the clinical 
situation and grade of dermatitis on a case-by-case basis.  
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Tables/Figures 
 
 
 
 
RT volume RT dose 
(fx x dose [Gy]) 
Interval end 
RT – begin 
reaction (days) 
RT 
tech-
nique 
RRD/ 
ARD 
CTCAE 
grade  
Distance 
PTV/skin 
(min. [cm]) 
Max. skin 
dose 
(EQD2 (α/β=8); 
[Gy]) 
Humerus (r) 12x3* 37 3D RRD 3 <0.5 39.4 
Scapula (l) 6x5 59. 3D RRD 2 <0.5 40.5 
8.th rib (r) 5x5 40 3D RRD 2 <0.5 30.2 
T6 5x7 50 RA RRD 0-1 2.2 28.0 
T10 5x7 57 RA RRD 0-1 1.2 25.8 
T3 5x7 50 RA RRD 0 5.0 19.8 
SIJ (l) 5x4 2 3D ARD 2 1.2 18.0 
L1 5x4 2 3D ARD 1 1.8 21.8 
Mandible (l) 5x4 2 3D ARD 1 <0.5 25.8 
Acetabulum (l) 5x4 2 3D ARD 0 5.7 8.6 
Table 1: Details of all radiation treatments that led to either radiation recall dermatitis (RRD) or acute radiation 
dermatitis (ARD). Interval in days between end of radiation therapy and begin of the reaction. CTCAE: common 
terminology criteria for adverse events [6], l: left, r: right, RA: rapid arc, 3D: 3D conformal radiotherapy, *post-
operative radiotherapy 
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Author,  
Year 
Age, 
Gender 
Diagnosis Radiotherapy Dosage of 
sorafenib 
Onset of RRD 
after start of 
sorafenib 
Symptoms Therapy of RRD Outcome 
Stieb,  
2015 77, m HCC 
Bone 
metastases 
20-36 Gy 
2 x 400 mg 1 week 
• Erythematous rash, 
eczematous, 
dissemination, 
pruritus 
• Topical steroids and 
oral antihistamines 
• Sorafenib 
discontinued 
• Skin reaction decreased within 
2 weeks 
Hsieh*,  
2014 63, m HCC 
Liver SBRT 
6 x 8 Gy 300 mg daily 1 week 
• RRD grade 2 • Topical steroids 
• Sorafenib 
discontinued 
• Symptoms resolved after 10 
days 
Oh*,  
2013 50, m HCC 
Chest wall 
mass 
13 x 3 Gy 
2 x 400 mg 2 weeks 
• Erythematous patch, 
dry desquamation, 
dissemination, 
pruritus 
• Oral antihistamines 
• Sorafenib 
discontinued 
• Sorafenib was started again, no 
recurrent RRD 
Chung*,  
2010 38, m HCC 
Liver SBRT 
6 x 5 Gy 2 x 200 mg Several days 
• Progressive pruritus, 
fatigue, patchy 
hyperpigmentation, 
dry desquamation 
• Topical steroids 
• Sorafenib continued 
• Pruritus and skin changes 
resolved after 2-3 weeks 
• Sorafenib was escalated 
without exacerbation of RRD 
n.a.**,  
2008 51, m RCC n.a. n.a. n.a. 
• Vesicular rash, 
swelling, tenderness, 
pain 
• n.a. • n.a. 
Table 2: Present case and summary of reported cases of RRD in *MEDLINE and the **WHO database “VigiBase®” [22]; HCC: hepatocellular carcinoma, m: 
male, n.a.: not available, RCC: renal cell carcinoma, RRD: radiation recall dermatitis, SBRT: stereotactic radiotherapy 
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Figure 1: Correlation of radiation recall 
dermatitis (right humerus, left scapula, T10) 
and acute radiation dermatitis (L1) with 
radiation fields.  
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Figure 2: Punch biopsy of a lesion at the right thoracic wall. The histopathological finding revealed a 
vacuolization of the dermoepidermal junction, apoptotic keratinocytes with sparse perivascular lymphocytic 
infiltrate and few eosinophils. 
 
